- Home
- PHVS vs VERV Comparison
PHVS vs VERV Comparison
Compare PHVS & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- VERV
- Stock Information
- Founded
- PHVS 2015
- VERV 2018
- Country
- PHVS Switzerland
- VERV United States
- Employees
- PHVS N/A
- VERV N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- VERV Medicinal Chemicals and Botanical Products
- Sector
- PHVS Health Care
- VERV Health Care
- Exchange
- PHVS Nasdaq
- VERV Nasdaq
- Market Cap
- PHVS 980.9M
- VERV 1.0B
- IPO Year
- PHVS 2021
- VERV 2021
- Fundamental
- Price
- PHVS $22.32
- VERV $11.06
- Analyst Decision
- PHVS Buy
- VERV Buy
- Analyst Count
- PHVS 6
- VERV 11
- Target Price
- PHVS $37.17
- VERV $14.57
- AVG Volume (30 Days)
- PHVS 33.8K
- VERV 7.7M
- Earning Date
- PHVS 08-13-2025
- VERV 08-07-2025
- Dividend Yield
- PHVS N/A
- VERV N/A
- EPS Growth
- PHVS N/A
- VERV N/A
- EPS
- PHVS N/A
- VERV N/A
- Revenue
- PHVS N/A
- VERV $59,613,000.00
- Revenue This Year
- PHVS N/A
- VERV $47.32
- Revenue Next Year
- PHVS N/A
- VERV N/A
- P/E Ratio
- PHVS N/A
- VERV N/A
- Revenue Growth
- PHVS N/A
- VERV 271.44
- 52 Week Low
- PHVS $11.51
- VERV $2.87
- 52 Week High
- PHVS $25.76
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- PHVS 73.31
- VERV 78.23
- Support Level
- PHVS $17.63
- VERV $11.16
- Resistance Level
- PHVS $19.00
- VERV $11.30
- Average True Range (ATR)
- PHVS 1.20
- VERV 0.12
- MACD
- PHVS 0.35
- VERV -0.18
- Stochastic Oscillator
- PHVS 92.15
- VERV 12.50
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.